Crimson Canary has an unbelievably good summary of Aurora kinase efforts, totally obviating a similar list that I kept in a messy excel sheet.
Hat tip to the Maestro of Mean Med Chem, the Sultan of Cynical Solubility, KinasePro :) .
Showing posts with label Aurora. Show all posts
Showing posts with label Aurora. Show all posts
Tuesday, January 23, 2007
Monday, November 13, 2006
MP-529 (Supergen)
Supergen (SUPG) provided an update on MP-529, a very selective Aurora A inhibitor. In addition to MP-529, Supergen also revealed data pertaining to a an Axl inhibitor (SGI-AXL-277), and Pim and Plk inhibitors.
SUPG has an interesting selection of targets. Pim, Plk, and Axl aren't yet of wide interest, meaning that SUPG is taking on enormous target biology risk in addition to the native chemistry/drug development risk.
SUPG is valued at ~$275M, with cash on hand of ~$75M.
SUPG has an interesting selection of targets. Pim, Plk, and Axl aren't yet of wide interest, meaning that SUPG is taking on enormous target biology risk in addition to the native chemistry/drug development risk.
SUPG is valued at ~$275M, with cash on hand of ~$75M.
Subscribe to:
Posts (Atom)
